Determination of norvancomycin epidemiological cut-off values (ECOFFs) for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 03 03 2020
accepted: 08 09 2020
pubmed: 16 10 2020
medline: 25 6 2021
entrez: 15 10 2020
Statut: ppublish

Résumé

To determine the epidemiological cut-off values (ECOFFs) of norvancomycin for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis. We collected 1199 clinical isolates of Staphylococcus species from five laboratories located in four cities in China. MICs and inhibitory zone diameters of norvancomycin were determined by broth microdilution and the disc diffusion method, separately. ECOFFs of norvancomycin for four species were calculated by ECOFFinder software following EUCAST principles. Methicillin and vancomycin resistance genes (mecA/mecC and vanA/vanB/vanC/vanD/vanE) were screened for by PCR in all isolates. Pearson correlation and χ2 test were used to calculate the correlation of MICs and inhibition zone diameters, and MICs and resistance genes, respectively. MICs of norvancomycin for all strains from five laboratories fell in the range of 0.12-2 mg/L. ECOFFs of norvancomycin were determined to be 2 mg/L for S. epidermidis and S. haemolyticus and 1 mg/L for S. aureus and S. hominis. A weak correlation was observed between MIC values and zone diameters for S. haemolyticus (r = -0.36) and S. hominis (r = -0.26), while no correlation was found for S. epidermidis and S. aureus. The mecA gene was detected in 63.1% of Staphylococcus, whereas no isolate carried mecC, vanA, vanB, vanC, vanD or vanE. ECOFFs of norvancomycin were not correlated with mecA gene carriage in Staphylococcus species. ECOFFs of norvancomycin for four Staphylococcus species were determined, which will be helpful to differentiate WT strains. The correlation of MICs and zone diameters of norvancomycin was weak in Staphylococcus species.

Identifiants

pubmed: 33057728
pii: 5923762
doi: 10.1093/jac/dkaa414
doi:

Substances chimiques

Anti-Bacterial Agents 0
Vancomycin 6Q205EH1VU
norvancomycin BP129IOC93

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-159

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Qiwen Yang (Q)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Xue Li (X)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Peiyao Jia (P)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Christian Giske (C)

EUCAST Development Laboratory for Antimicrobial Susceptibility Testing, c/o Clinical Microbiology, Central Hospital, Växjö, Sweden.

Gunnar Kahlmeter (G)

EUCAST Development Laboratory for Antimicrobial Susceptibility Testing, c/o Clinical Microbiology, Central Hospital, Växjö, Sweden.

John Turnidge (J)

Pathology, Paediatrics and Molecular Biosciences, University of Adelaide, SA, Australia.

Yunsong Yu (Y)

Department of Clinical Infectious Diseases, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.

Yuan Lv (Y)

Institute of Clinical Pharmacology, Peking University, Beijing, China.

Minggui Wang (M)

Huashan Hospital of Fudan University, Shanghai, China.

Ziyong Sun (Z)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Jie Lin (J)

Department of Clinical Infectious Diseases, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.

Yun Li (Y)

Institute of Clinical Pharmacology, Peking University, Beijing, China.

Bo Zheng (B)

Institute of Clinical Pharmacology, Peking University, Beijing, China.

Fupin Hu (F)

Huashan Hospital of Fudan University, Shanghai, China.

Yan Guo (Y)

Huashan Hospital of Fudan University, Shanghai, China.

Zhongju Chen (Z)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Haixia Li (H)

Department of Clinical Laboratory, Peking University First Hospital, Beijing, China.

Ge Zhang (G)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Jingjia Zhang (J)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Wei Kang (W)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Simeng Duan (S)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Tong Wang (T)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Ran Jing (R)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Yingchun Xu (Y)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH